Interstitial lung abnormalities (ILAs) are parenchymal lung changes found on high-resolution CT. In routine use of high-resolution CT, non-specific findings are frequently reported, which has prompted ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts.

The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

A 79-year-old man with recurrent oropharyngeal cancer has developed the first documented case of severe drug-induced interstitial lung disease following photoimmunotherapy with cetuximab-sarotalocan ...

Researchers in Japan have successfully generated lung cells similar to alveolar epithelial type 2 (AT2) cells from mouse ...

Arturo Loaiza-Bonilla, MD, MSEd, systemwide chief of hematology and oncology at St. Lukes University Health Network and ...

The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

In this study, an up-regulation of serine/arginine-rich splicing factor 7 (SRSF7) was identified in lung fibroblasts derived from IPF patients and a bleomycin (BLM)-induced mouse model, and further ...

A book created to help young children understand Pulmonary Fibrosis has received a very special reception at the Northern Ireland Assembly. The creators of the book, 'Pete the Puffling's Brave ...

The FDA approves a rapid test for identifying patients with NSCLC eligible for sunvozertinib, enhancing timely, precision ...

Fibroblasts reprogrammed into AT2-like lung cells in just 7–10 days, offering a faster, safer alternative to stem cell ...